Want to see STTK full AI Analyst Report?

Shattuck Labs (STTK) Price & Analysis

267 Followers

STTK Stock Chart & Stats

$7.43

$0.34(4.80%)

At close: Jul 24 4:00 PM EDT

$7.43

$0.34(4.80%)

Day’s Range― - ―

52-Week Range$0.90 - $8.33

Previous CloseN/A

Volume1.47M

Average Volume (3M)1.66M

Market Cap

$755.74M

Enterprise Value$695.04

Total Cash (Recent Filing)$63.30M

Total Debt (Recent Filing)$2.67M

Price to Earnings (P/E)―

Beta1.86

Next Earnings

Nov 10, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding100,363,250

10 Day Avg. Volume1,569,073

30 Day Avg. Volume1,655,662

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)3.08

Price to Sales (P/S)253.99

P/FCF Ratio-6.36

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$14.60

Price Target Upside96.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.48

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Extended Cash RunwayThe enlarged cash position gives Shattuck several years to advance clinical programs without immediate financing pressure. This supports trial continuity, preserves strategic flexibility, and increases the likelihood of reaching important development milestones.

Promising SL-325 Clinical ProfileDurable target engagement and a favorable early safety profile strengthen SL-325’s clinical differentiation. If confirmed in Phase 2b, these characteristics could support adoption in Crohn’s disease and create meaningful pipeline value.

Low Financial LeverageMinimal debt reduces fixed financial obligations and limits solvency risk while the company funds clinical development. The relatively strong asset base also provides flexibility to allocate capital toward trials, manufacturing, and regulatory preparation.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow means Shattuck cannot currently fund its activities from operations. Continued trial execution will consume substantial capital, making future financing or partnering important to maintain development momentum.

Minimal Revenue And Large LossesThe company remains far from commercial scale and break-even, with negligible revenue relative to its research costs. Its long-term financial performance therefore depends on clinical success and eventual commercialization rather than established operating income.

Equity Financing And Dilution RiskThe large equity and warrant financing improves liquidity but expands the potential share count. Repeated reliance on equity capital can dilute existing holders and signals that advancing the pipeline requires substantial external funding.

Shattuck Labs News

Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Shattuck Labs (STTK) to $14 from $18...

12d ago

STTK

Shattuck Labs reports Q2 EPS (12c), consensus (12c)

As of June 30, 2026, cash and cash equivalents and short-term investments were $208.3M, as compared to $50.5...

12d ago

STTK

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Shattuck Labs, Inc. is launching a...

11d ago

STTK

Buy Rating Reaffirmed on Shattuck Labs as De-Risked SL-325 Strategy and Strong Cash Runway Support Unchanged $18 Price Target

In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on Shattuck Labs, with a...

11d ago

STTK

Analyst Reaffirms Buy on Shattuck Labs, Maintains $17 Price Target on TL1A Pipeline Progress

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Shattuck Labs. The associated price target remains...

12d ago

STTK

SpaceX initiated, PayPal upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

ACI

Shattuck Labs initiated with an Overweight at JPMorgan

JPMorgan analyst Brian Cheng initiated coverage of Shattuck Labs (STTK) with an Overweight rating and $10 price target...

1M ago

STTK

Netflix upgraded, Microsoft initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

CRM

GPN

Shattuck Labs initiated with an Outperform at Leerink

Leerink initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $16 price target The firm says...

1M ago

STTK

Shattuck Labs initiated with an Outperform at Leerink

Leerink initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $16 price target Published first on...

1M ago

STTK

Shattuck Labs Prices Upsized Public Equity and Warrant Offering

Shattuck Labs ( ($STTK) ) just unveiled an announcement. On June 9, 2026, Shattuck Labs, Inc. entered into...

2M ago

STTK

Shattuck Labs 10.9M share Spot Secondary priced at $4.00

The deal range was $4.00-$4.25. Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald acted as joint book running managers...

2M ago

STTK

Shattuck Labs Reports Promising Phase 1 Data for SL-325

Shattuck Labs ( ($STTK) ) has issued an announcement. On June 8, 2026, Shattuck Labs reported Phase 1...

2M ago

STTK

Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25

Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald are acting as joint book running managers for the offering. Published...

2M ago

STTK

STTK FAQ

What was Shattuck Labs, Inc.’s price range in the past 12 months?

Shattuck Labs, Inc. lowest stock price was $0.90 and its highest was $8.33 in the past 12 months.

What is Shattuck Labs, Inc.’s market cap?

Shattuck Labs, Inc.’s market cap is $755.74M.

When is Shattuck Labs, Inc.’s upcoming earnings report date?

Shattuck Labs, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.

How were Shattuck Labs, Inc.’s earnings last quarter?

Shattuck Labs, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.004.

Is Shattuck Labs, Inc. overvalued?

According to Wall Street analysts Shattuck Labs, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shattuck Labs, Inc. pay dividends?

Shattuck Labs, Inc. does not currently pay dividends.

What is Shattuck Labs, Inc.’s EPS estimate?

Shattuck Labs, Inc.’s EPS estimate is -0.1.

How many shares outstanding does Shattuck Labs, Inc. have?

Shattuck Labs, Inc. has 100,363,250 shares outstanding.

What happened to Shattuck Labs, Inc.’s price movement after its last earnings report?

Shattuck Labs, Inc. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went up 0.56%.

Which hedge fund is a major shareholder of Shattuck Labs, Inc.?

Currently, no hedge funds are holding shares in STTK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shattuck Labs Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

242.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shattuck Labs, Inc.

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Shattuck Labs (STTK) Earnings & Revenues

Historic Earnings Reports

STTK Stock 12 Month Forecast

Average Price Target

$14.60

▲(96.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4,9,14,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.910769230769231,8.751538461538463,9.592307692307692,10.433076923076923,11.273846153846154,12.114615384615384,12.955384615384615,13.796153846153846,14.636923076923077,15.477692307692308,16.318461538461538,17.159230769230767,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.649230769230769,8.228461538461538,8.807692307692308,9.386923076923077,9.966153846153846,10.545384615384616,11.124615384615385,11.703846153846154,12.283076923076923,12.862307692307692,13.441538461538462,14.02076923076923,{"y":14.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.372307692307692,7.674615384615385,7.976923076923077,8.27923076923077,8.581538461538461,8.883846153846154,9.186153846153847,9.48846153846154,9.79076923076923,10.093076923076923,10.395384615384614,10.697692307692307,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >